Our Technology
We strive to meet the obvious unmet need for the next generation treatments for diabetes.
We are developing hiPSC-based pancreatic islet cells for cell replacement therapy, that will dramatically transform and improve the lives of diabetes patients who are highly dependent on exogenous insulin injections.
This therapy is to be offered as a curative treatment for Type 1 diabetes (T1D), other forms of insulin-dependent diabetes, as well as a treatment option for Type 2 diabetes (T2D) patients.
Therapeutics Pipeline
- Autologous hiPSC-derived pancreatic islet cells 66%
- Allogeneic hiPSC-derived pancreatic islet cells 66%
- Hypoimmunogenic hiPSC-derived pancreatic islet cells 33%
Discovery
Pre-Clinical
Clinical
Research Products and Services Pipeline
- Research-grade hiPSC lines (healthy and diabetic) 100%
- Research-grade hiPSC-derived pancreatic and islet cells (healthy and diabetic) 100%
- Custom generation of hiPSCs 100%
- cGMP-grade hiPSC lines 50%